Shuangxing Yu

发表

Convergence of Multiple Signaling Cascades at Glycogen Synthase Kinase 3: Edg Receptor-Mediated Phosphorylation and Inactivation by Lysophosphatidic Acid through a Protein Kinase C-Dependent Intracellular Pathway

G. Mills, Yiling Lu, J. Woodgett, 2002, Molecular and Cellular Biology.

Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway

G. Mills, R. Bast, M. Mao, 1999, Oncogene.

Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling

Luay Nakhleh, Yiling Lu, Kakajan Komurov, 2011, Oncogene.

The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers.

Leng Han, Yang Yang, Jun Li, 2015, Cancer cell.

Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer

G. Mills, S. Scherer, R. Verhaak, 2012, Genome research.

Lysophosphatidic acid is a bioactive mediator in ovarian cancer.

Gordon B Mills, Janos L Tanyi, G. Mills, 2002, Biochimica et biophysica acta.

Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases.

Yiling Lu, Gordon B Mills, Fan Zhang, 2009, Cancer cell.

Mechanisms for Lysophosphatidic Acid-induced Cytokine Production in Ovarian Cancer Cells*

G. Mills, R. Bast, Yiling Lu, 2004, Journal of Biological Chemistry.

A-toI RNA Editing Contrib utes to Proteomic Diversity in Cancer Graphical

G. Mills, Yiling Lu, P. Hwu, 2018 .

Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer.

G. Mills, R. Bast, X. Fang, 2006, Cancer research.

Lysophosphatidic Acid Is a Major Regulator of Growth-Regulated Oncogene α in Ovarian Cancer

G. Mills, R. Bast, X. Fang, 2006 .

Ovarian Cancer α Growth-Regulated Oncogene Lysophosphatidic Acid Is a Major Regulator of Updated

G. Mills, R. Bast, X. Fang, 2006 .

Phosphorothioate Analogues of Alkyl Lysophosphatidic Acid as LPA3 Receptor‐Selective Agonists

G. Mills, G. Prestwich, Y. Fujiwara, 2006, ChemMedChem.

Identification of a Phosphothionate Analogue of Lysophosphatidic Acid (LPA) as a Selective Agonist of the LPA3 Receptor*

G. Mills, X. Fang, J. R. Erickson, 2003, The Journal of Biological Chemistry.

PharmacodynamicMarkers of Perifosine Efficacy

G. Mills, M. Carey, Yiling Lu, 2007 .

Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers.

Leng Han, Jun Li, Yiling Lu, 2017, Genome research.

Pharmacodynamic Markers of Perifosine Efficacy

Yiling Lu, Gordon B. Mills, Vikas Kundra, 2007, Clinical Cancer Research.

Homozygous deletion of glycogen synthase kinase 3β bypasses senescence allowing Ras transformation of primary murine fibroblasts

G. Mills, J. Woodgett, Jinsong Liu, 2008, Proceedings of the National Academy of Sciences.

Systematic Functional Annotation of Somatic Mutations in Cancer.

Ken Chen, Li Ding, Jun Li, 2018, Cancer cell.

Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages.

Yiling Lu, Gordon B Mills, Vikas Kundra, 2006, Cancer cell.

Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors.

Yiling Lu, Gordon B Mills, Zhenlin Ju, 2014, Cancer cell.

High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.

G. Mills, S. Scherer, Z. Ju, 2011, Cancer discovery.

Nucleosome organization in sequences of alternative events in human genome

Xiao Sun, Hongde Liu, Huan Huang, 2012, Biosyst..

Analysis of nucleosome positioning determined by DNA helix curvature in the human genome

Xiao Sun, Hongde Liu, Xueye Duan, 2011, BMC Genomics.

Notice of RetractionChromatin Organization in Different Types of Splicing Events

Xiao Sun, Hongde Liu, Hongde Liu, 2011, 2011 5th International Conference on Bioinformatics and Biomedical Engineering.

Glycogen Synthase Kinase 3β Is a Negative Regulator of Growth Factor-induced Activation of the c-Jun N-terminal Kinase*

G. Mills, J. Woodgett, R. Lapushin, 2004, Journal of Biological Chemistry.

Functional lipidomics: Lysophosphatidic acid as a target for molecular diagnosis and therapy of ovarian cancer

Gordon B. Mills, Glenn D. Prestwich, Janos L. Tanyi, 2005 .

A-to-I RNA Editing Contributes to Proteomic Diversity in Cancer.

Leng Han, Yiling Lu, Zhicheng Zhou, 2018, Cancer cell.

Molecular therapeutics: promise and challenges.

G. Mills, E. Kohn, G. Hortobagyi, 2004, Seminars in oncology.

Implementation of a Multiplex and Quantitative Proteomics Platform for Assessing Protein Lysates Using DNA-Barcoded Antibodies*

G. Mills, Z. Ju, Z. Ding, 2018, Molecular & Cellular Proteomics.

Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells.

Yiling Lu, Gordon B Mills, Jinsong Liu, 2008, Journal of the National Cancer Institute.

Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer.

Prahlad T. Ram, G. Mills, P. Ram, 2016, Cell reports.

Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers.

G. Mills, A. Børresen-Dale, K. Chin, 2014, Cancer cell.

A-to-I-edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis.

G. Mills, Yiling Lu, A. Sood, 2019, The Journal of clinical investigation.

Abortive Autophagy Induces Endoplasmic Reticulum Stress and Cell Death in Cancer Cells

Jennifer B Dennison, G. Mills, Yiling Lu, 2012, PloS one.

Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid

G. Mills, G. Prestwich, Shuangxing Yu, 2010, Molecular Cancer.

The Genomic Landscape a nd Clinical Relevance of A-toI RNA Editing in Human Cancers Graphical

G. Mills, Z. Ju, Yiling Lu, 2015 .

Lysophosphatidic acid (LPA)‐induced vasodilator‐stimulated phosphoprotein mediates lamellipodia formation to initiate motility in PC‐3 prostate cancer cells

Gordon B Mills, Gabor Tigyi, G. Mills, 2008, Molecular oncology.

Lysophosphatidic acid production and action: Validated targets in cancer?

G. Mills, K. Aldape, G. Prestwich, 2004, Journal of cellular biochemistry.

Lysophosphatidic Acid-Induced Transcriptional Profile Represents Serous Epithelial Ovarian Carcinoma and Worsened Prognosis

Yiling Lu, Gordon B. Mills, G. Mills, 2009, PloS one.

Systematic Functional Ann otation of Somatic Mutations in Cancer Graphical

Amber M. Johnson, G. Mills, Ken Chen, 2018 .

Patient derived mutation W257G of PPP2R1A enhances cancer cell migration through SRC-JNK-c-Jun pathway

G. Mills, Ae Lee Jeong, Young Yang, 2016, Scientific Reports.

Structure-activity relationships of fluorinated lysophosphatidic acid analogues.

G. Mills, G. Prestwich, Shuangxing Yu, 2005, Journal of medicinal chemistry.

A-toI – edited miRNA-379-5 p inhibits cancer cell proliferation through CD 97-induced apoptosis

G. Mills, Yiling Lu, A. Sood, 2019 .

Erratum: Lysophosphatidic acid production and action: Validated targets in cancer? (Journal of Cellular Biochemistry (2004) 92 (1115-1140))

G. Mills, K. Aldape, G. Prestwich, 2004 .

Glycogen synthase kinase 3beta is a negative regulator of growth factor-induced activation of the c-Jun N-terminal kinase.

G. Mills, J. Woodgett, R. Lapushin, 2004, The Journal of biological chemistry.

Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells.

G. Mills, Yiling Lu, Jinsong Liu, 2008, Journal of the National Cancer Institute.

Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid

G. Mills, G. Prestwich, Shuangxing Yu, 2010, Molecular Cancer.

Open Access Research

Shuangxing Yu, Mandi M. Murph, G. Jiang, 2022 .

Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers.

Prahlad T. Ram, G. Mills, A. Børresen-Dale, 2014, Cancer cell.

Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors.

G. Mills, Z. Ju, Yiling Lu, 2014, Cancer cell.

The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers.

G. Mills, Z. Ju, Yiling Lu, 2015, Cancer cell.